5 Biotech Stocks in Billionaire Ray Dalio’s Portfolio

2. AstraZeneca PLC (NASDAQ:AZN)

Bridgewater Associates’ Stake Value: $6.2 million

Percentage of Bridgewater Associates’ 13F Portfolio: 0.03%

Number of Hedge Fund Holders: 41

Closing price on December 10, 2021: $54.02

AstraZeneca PLC (NASDAQ:AZN) is a medicine manufacturer for ailments of the heart, cancer, lungs, digestive system, and other areas. It also develops and sells a vaccine for the COVID-19 coronavirus virus.

For its Q3, AstraZeneca PLC (NASDAQ:AZN) brought in $9.8 billion revenue and a GAAP EPS of $1.08, as it pleased Wall Street by exceeding analyst estimates for both. In a November 2021 analyst note, Bryan Garnier set the company’s price target to GBp 10,500.

Mr. Dalio’s Bridgewater Associates owned 104,233 AstraZeneca PLC (NASDAQ:AZN) shares as of Q3 2021. This let him have a stake of $6.2 million, which made up 0.03% of the firm’s portfolio. During the same time period, 41 of 876 hedge funds polled by Insider Monkey owned AstraZeneca PLC (NASDAQ:AZN)’s shares.

AstraZeneca PLC (NASDAQ:AZN)’s closing share price was $54.02 on December 10, 2021.

Ken Fisher’s Fisher Asset Management is AstraZeneca PLC (NASDAQ:AZN)’s largest shareholder through a $1.1 billion stake via owning 19 million shares.